The UK and US have secured a key trade agreement that will preserve no tariffs on UK medicine shipments entering the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to increase spending on drugs through the public health system. This commitment secures that import taxes on these vital products will remain at zero for a period of 36 months.
This deal is in response to earlier threats to dramatically increase import taxes on branded pharmaceutical imports, with increases mentioned up to one hundred percent.
"This agreement with the UK reinforces the global environment for innovative medicines and establishes long-overdue fairness to transatlantic medicine commerce," a statement noted.
Trade Significance
Drugs are one of the Britain's biggest export categories to the America, which is clearly the largest market for large UK drugmakers.
Export figures indicate that in the 12 months leading up to last September, the UK exported drugs valued at billions to the US. This value made up 17.4% of British export trade in that timeframe.
"This deal secures employment, increases investment and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official commented.
Key UK Commitments
The deal involves several notable changes from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. Previously, rebates exceeded 20%.
Broader Context
This agreement follows a protracted tension between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
This friction were intensified by arguments that American customers were paying several times more for the same drugs than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been delayed or cancelled, while major investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
